



Online Supplementary Material

Projected Reduction of Diabetes- and Obesity-Related Complication Risks Following the 12-week Weight-Loss Phase of the RESET Trial. *JHEOR*. 2026;13(1):255-263. [doi:10.36469/jheor.2026.162856](https://doi.org/10.36469/jheor.2026.162856)

Table S1: Projected Event Counts per 1000 Patients at Baseline and After the 12-Week Intervention

This supplementary material has been provided by the authors to give readers additional information about their work.



Table 1. Projected Event Counts per 1000 Patients at Baseline and After the 12-Week Intervention

Event Category	Baseline Events per 1000 Patients	Post-intervention Events per 1000 Patients	Absolute Reduction (Events/1000)	Relative Risk Reduction (%)
Congestive heart failure	2.34	1.79	0.55	-23.4
Ischemic heart disease	2.17	2.11	0.06	-2.6
Myocardial infarction	1.61	1.43	0.18	-10.9
Stroke	2.12	1.79	0.33	-15.5
All macrovascular events	8.23	7.13	1.10	-13.5
Blindness	0.85	0.69	0.16	-18.3
Foot ulcer	0.81	0.57	0.24	-29.9
Amputation	0.46	0.34	0.12	-24.9
Renal disease	0.20	0.16	0.04	-21.2
All microvascular events	2.32	1.77	0.55	-23.9
Total events (all categories)	11.98	10.13	1.85	-15.4